他汀類藥物調(diào)脂外作用在臨床應(yīng)用的研究進(jìn)展-全文預(yù)覽
【正文】 ：645—654.[26] giri j，mcdermott m m，greenland p，et al. statin use and functional decline in patients with and without peripheral arterial disease[j].j am coll cardiol，2006，47（5）：998—1004.[27] aronow w s，nayak d，woodworth s，et of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment[j].am j cardiol，2003，92（6）：711—712.[28] acc/aha 2005 practice guidelines for the management of patients with peripheral arterial disease （lower extremity， renal， mesenteric， and abdominal aortic）： a collaborative report from the american association for vascular surgery/society for vascular surgery， society for cardiovascular angiography and interventions， society for vascular medicine and biology， society of interventional radiology， and the acc/aha task force on practice guidelines （writing mittee to develop guidelines for the management of patients with peripheral arterial disease）： endorsed by the american association of cardiovascular and pulmonary rehabilitation； national heart， lung， and blood institute； society for vascular nursing； transatlantic inter—society consensus； and vascular disease foundation[j]. circulation，2006，113（11）：463—654.[29] the lipid study prevention of cardiovascular events with long—term pravastatin in patients with diabetes or impaired fasting glucose： results from the lipid trial[j].diabetes care，2003，26（10）：2713—2721.[30] the cards prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study （cards）：multicentre randomised placebo—controlled trial[j].lancet，2004，364（9435）：685—696.[31] cholesterol and recurrent events （care） trial investigators. pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency[j].ann intern med，2003，138（2）：98—104.[32] navaneethan s d，pansini f， perkovic v，et coa reductase inhibitors （statins） for people with chronic kidney disease not requiring dialysis[j].cochrane database syst rev，2009，15（2）：7784.[33] aurora study and cardiovascular events in patients undergoing hemodialysis[j].n engl j med，2009，360（14）：1395—1407.[34] national kidney [j].am j kidney dis，2003，41（3）：1—91.（收稿日期：2012—06—26） （編輯：王春蕓）。然而，總體而言，他汀類藥物治療的依從性仍然不理想，這與患者、醫(yī)師和經(jīng)濟因素都有關(guān)系。指南認(rèn)為ckd的任何階段均為冠心病等危癥，并建議ckd患者ldl100 mg/dl。最近一項涉及26個試驗，超過25 000例不需透析的ckd患者的薈萃研究顯示他汀治療可以明顯降低死亡率，而沒有增加不良事件的發(fā)生[32]。對于已患有cvd的患者，不管血脂的基線水平如何，ldl應(yīng)低于70 mg/dl。cards試驗[
環(huán)評公示相關(guān)推薦
鄂ICP備17016276號-1